The estimated Net Worth of Anand Sofinnova Venture Par... is at least 1.06 百万$ dollars as of 20 October 2016. Anand Par owns over 750,683 units of Marinus Pharmaceuticals Inc stock worth over 21,503$ and over the last 10 years Anand sold MRNS stock worth over 1,043,449$.
Anand has made over 2 trades of the Marinus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Anand sold 750,683 units of MRNS stock worth 1,043,449$ on 20 October 2016.
The largest trade Anand's ever made was selling 750,683 units of Marinus Pharmaceuticals Inc stock on 20 October 2016 worth over 1,043,449$. On average, Anand trades about 750,683 units every 404 days since 2014. As of 20 October 2016 Anand still owns at least 15,470 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Anand Par stock trades at the bottom of the page.
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over 13,562,679$ worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth 19,488,416$ . The most active insiders traders include Nicole Vitullo、Capital Life Sciences Inves...、Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of 149,293$. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth 4,355$.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: